Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1998 Jan 15;101(2):372–382. doi: 10.1172/JCI522

Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium.

M M Bitzan 1, Y Wang 1, J Lin 1, P A Marsden 1
PMCID: PMC508576  PMID: 9435309

Abstract

Interaction of bipartite Escherichia coli O157-derived verotoxins (VTs) 1 and 2 (Shiga toxin 1 and 2) with vascular endothelium is believed to play a central role in the pathogenesis of the thrombotic microangiopathy and ischemic lesions characteristic of hemolytic uremic syndrome and of E. coli O157-associated hemorrhagic colitis. We defined the effects of VTs on the expression of potent endothelial cell-derived regulators of vascular wall function, namely endothelin-1 (ET-1) and nitric oxide (NO). In quiescent bovine aortic endothelial cells, both VT1 and VT2, but not receptor-binding VT B-subunit which lacks N-glycosidase activity, induced concentration-dependent (0.1-10 nM) increases in steady state preproET-1 mRNA transcript levels, an effect that was maximal at 12-24 h. Metabolic-labeling experiments indicated that VTs increased preproET-1 mRNA transcript levels at concentrations that had trivial effects on nascent DNA, RNA, and protein synthesis. In contrast to preproET-1, endothelin converting enzyme-1 and endothelial constitutive NO synthase mRNA transcript levels remained unchanged. Consistent with these findings, VTs failed to modulate immunoreactive endothelial constitutive NO synthase expression and basal and calcium-dependent L-[14C]arginine to L-[14C]citrulline conversion or the NO chemiluminescence signal. The plant-derived toxin ricin, which shows a similar molecular mechanism of enzymatic ribosomal modification to VTs, caused comparable effects on these endothelial vasomediators and metabolite incorporation, at 3 log orders lower concentrations. Nuclear transcription and actinomycin D chase experiments indicated that VTs stabilize labile preproET-1 mRNA transcripts in endothelial cells. Therefore, VTs potently increase select mRNA transcript levels in endothelial cells at concentrations of toxins that have minimal effects on protein synthesis. Perturbed expression of endothelial-derived vasomediators may play a pathophysiologic role in the microvascular dysfunction that is the hallmark of hemolytic uremic syndrome and hemorrhagic colitis.

Full Text

The Full Text of this article is available as a PDF (437.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Argyle J. C., Hogg R. J., Pysher T. J., Silva F. G., Siegler R. L. A clinicopathological study of 24 children with hemolytic uremic syndrome. A report of the Southwest Pediatric Nephrology Study Group. Pediatr Nephrol. 1990 Jan;4(1):52–58. doi: 10.1007/BF00858440. [DOI] [PubMed] [Google Scholar]
  2. Benigni A., Remuzzi G. The role of eicosanoids in the pathogenesis of hemolytic uremic syndrome. Prostaglandins Leukot Essent Fatty Acids. 1994 Aug;51(2):75–79. doi: 10.1016/0952-3278(94)90081-7. [DOI] [PubMed] [Google Scholar]
  3. Bergstein J. M., Riley M., Bang N. U. Role of plasminogen-activator inhibitor type 1 in the pathogenesis and outcome of the hemolytic uremic syndrome. N Engl J Med. 1992 Sep 10;327(11):755–759. doi: 10.1056/NEJM199209103271102. [DOI] [PubMed] [Google Scholar]
  4. Biragyn A., Nedospasov S. A. Lipopolysaccharide-induced expression of TNF-alpha gene in the macrophage cell line ANA-1 is regulated at the level of transcription processivity. J Immunol. 1995 Jul 15;155(2):674–683. [PubMed] [Google Scholar]
  5. Bitzan M., Ludwig K., Klemt M., König H., Büren J., Müller-Wiefel D. E. The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study. Epidemiol Infect. 1993 Apr;110(2):183–196. doi: 10.1017/s0950268800068102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bredt D. S., Snyder S. H. Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum. Proc Natl Acad Sci U S A. 1989 Nov;86(22):9030–9033. doi: 10.1073/pnas.86.22.9030. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Brooks D. P. Role of endothelin in renal function and dysfunction. Clin Exp Pharmacol Physiol. 1996 Apr;23(4):345–348. doi: 10.1111/j.1440-1681.1996.tb02835.x. [DOI] [PubMed] [Google Scholar]
  8. Crisp D. E., Siegler R. L., Bale J. F., Thompson J. A. Hemorrhagic cerebral infarction in the hemolytic-uremic syndrome. J Pediatr. 1981 Aug;99(2):273–276. doi: 10.1016/s0022-3476(81)80476-3. [DOI] [PubMed] [Google Scholar]
  9. Downes F. P., Barrett T. J., Green J. H., Aloisio C. H., Spika J. S., Strockbine N. A., Wachsmuth I. K. Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect Immun. 1988 Aug;56(8):1926–1933. doi: 10.1128/iai.56.8.1926-1933.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Farkas-Himsley H., Hill R., Rosen B., Arab S., Lingwood C. A. The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc Natl Acad Sci U S A. 1995 Jul 18;92(15):6996–7000. doi: 10.1073/pnas.92.15.6996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Flowers M. A., Wang Y., Stewart R. J., Patel B., Marsden P. A. Reciprocal regulation of endothelin-1 and endothelial constitutive NOS in proliferating endothelial cells. Am J Physiol. 1995 Dec;269(6 Pt 2):H1988–H1997. doi: 10.1152/ajpheart.1995.269.6.H1988. [DOI] [PubMed] [Google Scholar]
  12. Furutani M., Kashiwagi K., Ito K., Endo Y., Igarashi K. Comparison of the modes of action of a Vero toxin (a Shiga-like toxin) from Escherichia coli, of ricin, and of alpha-sarcin. Arch Biochem Biophys. 1992 Feb 14;293(1):140–146. doi: 10.1016/0003-9861(92)90376-8. [DOI] [PubMed] [Google Scholar]
  13. Gerez L., Arad G., Efrat S., Ketzinel M., Kaempfer R. Post-transcriptional regulation of human interleukin-2 gene expression at processing of precursor transcripts. J Biol Chem. 1995 Aug 18;270(33):19569–19575. doi: 10.1074/jbc.270.33.19569. [DOI] [PubMed] [Google Scholar]
  14. Gómez-Garre D., Largo R., Liu X. H., Gutierrez S., López-Armada M. J., Palacios I., Egido J. An orally active ETA/ETB receptor antagonist ameliorates proteinuria and glomerular lesions in rats with proliferative nephritis. Kidney Int. 1996 Sep;50(3):962–972. doi: 10.1038/ki.1996.397. [DOI] [PubMed] [Google Scholar]
  15. Harel Y., Silva M., Giroir B., Weinberg A., Cleary T. B., Beutler B. A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. J Clin Invest. 1993 Nov;92(5):2110–2116. doi: 10.1172/JCI116811. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hof R. P., Hof A., Takiguchi Y. Massive regional differences in the vascular effects of endothelin. J Hypertens Suppl. 1989 Dec;7(6):S274–S275. doi: 10.1097/00004872-198900076-00133. [DOI] [PubMed] [Google Scholar]
  17. Inagaki H., Bishop A. E., Escrig C., Wharton J., Allen-Mersh T. G., Polak J. M. Localization of endothelinlike immunoreactivity and endothelin binding sites in human colon. Gastroenterology. 1991 Jul;101(1):47–54. doi: 10.1016/0016-5085(91)90458-w. [DOI] [PubMed] [Google Scholar]
  18. Iordanov M. S., Pribnow D., Magun J. L., Dinh T. H., Pearson J. A., Chen S. L., Magun B. E. Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol. 1997 Jun;17(6):3373–3381. doi: 10.1128/mcb.17.6.3373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Iwasaki S., Homma T., Matsuda Y., Kon V. Endothelin receptor subtype B mediates autoinduction of endothelin-1 in rat mesangial cells. J Biol Chem. 1995 Mar 24;270(12):6997–7003. doi: 10.1074/jbc.270.12.6997. [DOI] [PubMed] [Google Scholar]
  20. Jacobson A., Peltz S. W. Interrelationships of the pathways of mRNA decay and translation in eukaryotic cells. Annu Rev Biochem. 1996;65:693–739. doi: 10.1146/annurev.bi.65.070196.003401. [DOI] [PubMed] [Google Scholar]
  21. Karmali M. A., Steele B. T., Petric M., Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet. 1983 Mar 19;1(8325):619–620. doi: 10.1016/s0140-6736(83)91795-6. [DOI] [PubMed] [Google Scholar]
  22. Kawana M., Lee M. E., Quertermous E. E., Quertermous T. Cooperative interaction of GATA-2 and AP1 regulates transcription of the endothelin-1 gene. Mol Cell Biol. 1995 Aug;15(8):4225–4231. doi: 10.1128/mcb.15.8.4225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Knight B. Ricin--a potent homicidal poison. Br Med J. 1979 Feb 3;1(6159):350–351. [PMC free article] [PubMed] [Google Scholar]
  24. Kohan D. E. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 1997 Jan;29(1):2–26. doi: 10.1016/s0272-6386(97)90004-4. [DOI] [PubMed] [Google Scholar]
  25. Kuhn M., Fuchs M., Beck F. X., Martin S., Jähne J., Klempnauer J., Kaever V., Rechkemmer G., Forssmann W. G. Endothelin-1 potently stimulates chloride secretion and inhibits Na(+)-glucose absorption in human intestine in vitro. J Physiol. 1997 Mar 1;499(Pt 2):391–402. doi: 10.1113/jphysiol.1997.sp021936. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Kurose I., Miura S., Fukumura D., Tashiro H., Imaeda H., Shiozaki H., Suematsu M., Nagata H., Sekizuka E., Tsuchiya M. Role of platelet activating factor on the fibrinolytic activation in the pathogenesis of gastric mucosal damage induced by endothelin-1. Gut. 1992 Jul;33(7):868–871. doi: 10.1136/gut.33.7.868. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Lagnado C. A., Brown C. Y., Goodall G. J. AUUUA is not sufficient to promote poly(A) shortening and degradation of an mRNA: the functional sequence within AU-rich elements may be UUAUUUA(U/A)(U/A). Mol Cell Biol. 1994 Dec;14(12):7984–7995. doi: 10.1128/mcb.14.12.7984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Lamas S., Marsden P. A., Li G. K., Tempst P., Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci U S A. 1992 Jul 15;89(14):6348–6352. doi: 10.1073/pnas.89.14.6348. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Lamas S., Michel T., Brenner B. M., Marsden P. A. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by TNF-alpha. Am J Physiol. 1991 Oct;261(4 Pt 1):C634–C641. doi: 10.1152/ajpcell.1991.261.4.C634. [DOI] [PubMed] [Google Scholar]
  30. Lamas S., Michel T., Collins T., Brenner B. M., Marsden P. A. Effects of interferon-gamma on nitric oxide synthase activity and endothelin-1 production by vascular endothelial cells. J Clin Invest. 1992 Sep;90(3):879–887. doi: 10.1172/JCI115963. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Leone A. M., Rhodes P., Furst V., Moncada S. Techniques for the measurement of nitric oxide. Methods Mol Biol. 1995;41:285–299. doi: 10.1385/0-89603-298-1:285. [DOI] [PubMed] [Google Scholar]
  32. Linggood M. A., Thompson J. M. Verotoxin production among porcine strains of Escherichia coli and its association with oedema disease. J Med Microbiol. 1987 Dec;24(4):359–362. doi: 10.1099/00222615-24-4-359. [DOI] [PubMed] [Google Scholar]
  33. Lingwood C. A. Verotoxins and their glycolipid receptors. Adv Lipid Res. 1993;25:189–211. [PubMed] [Google Scholar]
  34. Lord J. M., Roberts L. M., Robertus J. D. Ricin: structure, mode of action, and some current applications. FASEB J. 1994 Feb;8(2):201–208. [PubMed] [Google Scholar]
  35. Marsden P. A., Brenner B. M. Nitric oxide and endothelins: novel autocrine/paracrine regulators of the circulation. Semin Nephrol. 1991 Mar;11(2):169–185. [PubMed] [Google Scholar]
  36. Marsden P. A., Brenner B. M. Transcriptional regulation of the endothelin-1 gene by TNF-alpha. Am J Physiol. 1992 Apr;262(4 Pt 1):C854–C861. doi: 10.1152/ajpcell.1992.262.4.C854. [DOI] [PubMed] [Google Scholar]
  37. Marsden P. A., Brock T. A., Ballermann B. J. Glomerular endothelial cells respond to calcium-mobilizing agonists with release of EDRF. Am J Physiol. 1990 May;258(5 Pt 2):F1295–F1303. doi: 10.1152/ajprenal.1990.258.5.F1295. [DOI] [PubMed] [Google Scholar]
  38. Marsden P. A., Dorfman D. M., Collins T., Brenner B. M., Orkin S. H., Ballermann B. J. Regulated expression of endothelin 1 in glomerular capillary endothelial cells. Am J Physiol. 1991 Jul;261(1 Pt 2):F117–F125. doi: 10.1152/ajprenal.1991.261.1.F117. [DOI] [PubMed] [Google Scholar]
  39. O'Brien A. D., Tesh V. L., Donohue-Rolfe A., Jackson M. P., Olsnes S., Sandvig K., Lindberg A. A., Keusch G. T. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol. 1992;180:65–94. doi: 10.1007/978-3-642-77238-2_4. [DOI] [PubMed] [Google Scholar]
  40. O'Brien J. A., Van Why S. K., Keller M. S., Gaudio K. M., Kennedy T. L., Siegel N. J. Altered renovascular resistance after spontaneous recovery from hemolytic uremic syndrome. Yale J Biol Med. 1994 Jan-Apr;67(1-2):1–14. [PMC free article] [PubMed] [Google Scholar]
  41. Oberbäumer I. Retroposons do jump: a B2 element recently integrated in an 18S rDNA gene. Nucleic Acids Res. 1992 Feb 25;20(4):671–677. doi: 10.1093/nar/20.4.671. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ostroff S. M., Tarr P. I., Neill M. A., Lewis J. H., Hargrett-Bean N., Kobayashi J. M. Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis. 1989 Dec;160(6):994–998. doi: 10.1093/infdis/160.6.994. [DOI] [PubMed] [Google Scholar]
  43. Radomski M. W., Palmer R. M., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet. 1987 Nov 7;2(8567):1057–1058. doi: 10.1016/s0140-6736(87)91481-4. [DOI] [PubMed] [Google Scholar]
  44. Ramegowda B., Tesh V. L. Differentiation-associated toxin receptor modulation, cytokine production, and sensitivity to Shiga-like toxins in human monocytes and monocytic cell lines. Infect Immun. 1996 Apr;64(4):1173–1180. doi: 10.1128/iai.64.4.1173-1180.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Ramotar K., Boyd B., Tyrrell G., Gariepy J., Lingwood C., Brunton J. Characterization of Shiga-like toxin I B subunit purified from overproducing clones of the SLT-I B cistron. Biochem J. 1990 Dec 15;272(3):805–811. doi: 10.1042/bj2720805. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Reid J. L., Dawson D., Macrae I. M. Endothelin, cerebral ischaemia and infarction. Clin Exp Hypertens. 1995 Jan-Feb;17(1-2):399–407. doi: 10.3109/10641969509087080. [DOI] [PubMed] [Google Scholar]
  47. Remuzzi G., Ruggenenti P. The hemolytic uremic syndrome. Kidney Int. 1995 Jul;48(1):2–19. doi: 10.1038/ki.1995.261. [DOI] [PubMed] [Google Scholar]
  48. Richardson S. E., Karmali M. A., Becker L. E., Smith C. R. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol. 1988 Sep;19(9):1102–1108. doi: 10.1016/s0046-8177(88)80093-5. [DOI] [PubMed] [Google Scholar]
  49. Richardson S. E., Rotman T. A., Jay V., Smith C. R., Becker L. E., Petric M., Olivieri N. F., Karmali M. A. Experimental verocytotoxemia in rabbits. Infect Immun. 1992 Oct;60(10):4154–4167. doi: 10.1128/iai.60.10.4154-4167.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Riley L. W., Remis R. S., Helgerson S. D., McGee H. B., Wells J. G., Davis B. R., Hebert R. J., Olcott E. S., Johnson L. M., Hargrett N. T. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med. 1983 Mar 24;308(12):681–685. doi: 10.1056/NEJM198303243081203. [DOI] [PubMed] [Google Scholar]
  51. Ross J. mRNA stability in mammalian cells. Microbiol Rev. 1995 Sep;59(3):423–450. doi: 10.1128/mr.59.3.423-450.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Rubanyi G. M., Polokoff M. A. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology. Pharmacol Rev. 1994 Sep;46(3):325–415. [PubMed] [Google Scholar]
  53. Sandvig K., Ryd M., Garred O., Schweda E., Holm P. K., van Deurs B. Retrograde transport from the Golgi complex to the ER of both Shiga toxin and the nontoxic Shiga B-fragment is regulated by butyric acid and cAMP. J Cell Biol. 1994 Jul;126(1):53–64. doi: 10.1083/jcb.126.1.53. [DOI] [PMC free article] [PubMed] [Google Scholar]
  54. Sandvig K., van Deurs B. Endocytosis and intracellular sorting of ricin and Shiga toxin. FEBS Lett. 1994 Jun 6;346(1):99–102. doi: 10.1016/0014-5793(94)00281-9. [DOI] [PubMed] [Google Scholar]
  55. Sawaf H., Sharp M. J., Youn K. J., Jewell P. A., Rabbani A. Ischemic colitis and stricture after hemolytic-uremic syndrome. Pediatrics. 1978 Feb;61(2):315–317. [PubMed] [Google Scholar]
  56. Shultz P. J., Raij L. Endogenously synthesized nitric oxide prevents endotoxin-induced glomerular thrombosis. J Clin Invest. 1992 Nov;90(5):1718–1725. doi: 10.1172/JCI116045. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Siegler R. L., Edwin S. S., Christofferson R. D., Mitchell M. D. Endothelin in the urine of children with the hemolytic uremic syndrome. Pediatrics. 1991 Nov;88(5):1063–1066. [PubMed] [Google Scholar]
  58. Siegler R. L. Spectrum of extrarenal involvement in postdiarrheal hemolytic-uremic syndrome. J Pediatr. 1994 Oct;125(4):511–518. doi: 10.1016/s0022-3476(94)70001-x. [DOI] [PubMed] [Google Scholar]
  59. Siegler R. L. The hemolytic uremic syndrome. Pediatr Clin North Am. 1995 Dec;42(6):1505–1529. doi: 10.1016/s0031-3955(16)40096-9. [DOI] [PubMed] [Google Scholar]
  60. Silkoff P. E., McClean P. A., Slutsky A. S., Furlott H. G., Hoffstein E., Wakita S., Chapman K. R., Szalai J. P., Zamel N. Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. Am J Respir Crit Care Med. 1997 Jan;155(1):260–267. doi: 10.1164/ajrccm.155.1.9001322. [DOI] [PubMed] [Google Scholar]
  61. Simpson J. C., Dascher C., Roberts L. M., Lord J. M., Balch W. E. Ricin cytotoxicity is sensitive to recycling between the endoplasmic reticulum and the Golgi complex. J Biol Chem. 1995 Aug 25;270(34):20078–20083. doi: 10.1074/jbc.270.34.20078. [DOI] [PubMed] [Google Scholar]
  62. Tarr P. I. Escherichia coli O157:H7: clinical, diagnostic, and epidemiological aspects of human infection. Clin Infect Dis. 1995 Jan;20(1):1–10. doi: 10.1093/clinids/20.1.1. [DOI] [PubMed] [Google Scholar]
  63. Tesh V. L., Ramegowda B., Samuel J. E. Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immun. 1994 Nov;62(11):5085–5094. doi: 10.1128/iai.62.11.5085-5094.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Vater C. A., Bartle L. M., Leszyk J. D., Lambert J. M., Goldmacher V. S. Ricin A chain can be chemically cross-linked to the mammalian ribosomal proteins L9 and L10e. J Biol Chem. 1995 May 26;270(21):12933–12940. doi: 10.1074/jbc.270.21.12933. [DOI] [PubMed] [Google Scholar]
  65. Wool I. G., Glück A., Endo Y. Ribotoxin recognition of ribosomal RNA and a proposal for the mechanism of translocation. Trends Biochem Sci. 1992 Jul;17(7):266–269. doi: 10.1016/0968-0004(92)90407-z. [DOI] [PubMed] [Google Scholar]
  66. Zubiaga A. M., Belasco J. G., Greenberg M. E. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol Cell Biol. 1995 Apr;15(4):2219–2230. doi: 10.1128/mcb.15.4.2219. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. van Setten P. A., Monnens L. A., Verstraten R. G., van den Heuvel L. P., van Hinsbergh V. W. Effects of verocytotoxin-1 on nonadherent human monocytes: binding characteristics, protein synthesis, and induction of cytokine release. Blood. 1996 Jul 1;88(1):174–183. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES